Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04989413
Other study ID # HIAE CAMTREA Protocol
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date October 18, 2022
Est. completion date April 19, 2024

Study information

Verified date January 2023
Source Hospital Israelita Albert Einstein
Contact Fernanda Assir
Phone +55 11 21510724
Email fernanda.assir@einstein.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the effect of the cannabidiol (CBD) + cannabigerol (CBG) + tetrahydrocannabinol (THC) up to 133/66/4mg daily versus placebo as adjuvant treatment in chronic migraine (CM) patients under preventive treatment at a stable dose for at least 3 months who present at least 5 headaches day a month. CM patients of both sexes, between 25 and 65 years old, who have not had CBD and/or THC as a migraine treatment. Patients may be having migraine preventive treatment such as propranolol, atenolol, topiramate, valproic acid/sodium valproate, levetiracetam, gabapentin, lamotrigine, pre-gabaline, flunarizine, amitriptyline, nortriptyline, clomipramine, candesartan, galcanezumab, erenumab, fremanezumab, botulinum toxin type A. Acute treatment will follow patients doctor's prescription. Exclusion criteria: active liver disease or elevated liver transaminases> 3 times than the normal values, pregnancy, fertile age women without contraceptive treatment or who intend to get pregnant, patients without migraine preventive treatment or that changed the preventive treatment less than 3 months from the study start, substance abuse or addiction, use of medical cannabis or products with CBD or THC in the last 30 days or during study period, history of allergy or adverse reactions with the use of CBD or related products, substance users of liver enzymes inducers such as rifampicin, ketoconazole, theophylline, carbamazepine, phenytoin, phenobarbital and St. John's wort, clobazam, macrolides, verapamil, fluoxetine, amiodarone and tacrolimus. Patients on vitamin K anticoagulant medicines, as warfarin. Randomization using a computacional system will stratify participants in each group by gender (F/M), age (25-34/35-44/45-54/55-65yo), headache days presented in the baseline month (5-10/11-15/16-20/21-25/26-30), overuse medication (yes or no). After randomization patients will be divided into two groups of 55 participants, who will receive CBD + CBG + THC up to a maximum daily dose of 133/66/4 mg or placebo for 12 weeks (V0 screening, V1 allocation, V4 final visit). The main outcome is the reduction in frequency of headache days per 4 weeks between V1 and V4 compared to placebo. Secondary outcomes will be a reduction in duration and intensity of migraine attacks, amount of painkillers used and percentage of patients with a reduction greater than 50% on migraine days, 50% reduction in the other variables as MIDAS scores, HIT-6 scores, Beck's Anxiety and Depression Scales, Epworth Sleepiness Scales, and the scores at The Severity of Dependence Scale used as an indicator of overuse medication in this sample. Clinical data will be registered on a personalized headache diary developed to this study using MyCap, from RedCap System, as an APP for daily entries using smartphones, androids or IOS system. The clinical and laboratory data obtained in this study will comply with the objectives elaborated in the evaluation of the primary and secondary endpoints, the proposal of which is to publish the data regardless of the results obtained.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date April 19, 2024
Est. primary completion date October 18, 2023
Accepts healthy volunteers No
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria: - Patients of both sexes, 25 to 65 years old, with chronic migraine according to IHS Classification System, 3rd edition - Undergoing preventive treatment in a stable dose of the preventive medication for at least 2 months, who have not used cannabidiol to treat migraine. - At least 5 days of migraine/migraine like attacks in the baseline period (4 weeks) - As preventive drugs propranolol, atenolol, topiramate, valproic acid/sodium valproate, levetiracetam, gabapentin, lamotrigine, pre-gabaline, flunarizine, amitriptyline, nortriptyline, clomipramine, candesartan, galcanezumab, erenumab, fremanezumab, botulinum toxin type A will be allowed. Patients whose preventive treatment for migraine is Botulinum Toxin Type A may participate in the study as long as the toxin application interval used is 4 months (duration of medication or placebo use) and who have already received treatment with toxin at least 2 times. - If acute treatment is necessary, patients may use the medications as previously advised by the physician accompanying them, and may use common, combined painkillers, anti-inflammatory drugs, triptans, triptans combined with anti-inflammatory drugs, opioid analgesics. Exclusion Criteria: - Patients with active liver disease - pregnancy and/or women who intend to become pregnant or who do not make adequate use of contraceptive therapy/methods - breastfeeding women - use of cannabis during the study, whether with therapeutic or recreational intentions - patients who are without preventive treatment or who have undergone a dose change in preventive migraine treatment less than two months before V1 . - Patients whose exclusive treatment for chronic migraine is Botulinum Toxin Type A at intervals of less than 4 months. - History of substance abuse or addiction, use of medical cannabis or products with CBD, CBG or THC in the last 30 days, history of allergy to CBD or related products - elevated transaminases > 3x the normal value - substance abusers - patients using substances that are potent enzyme inducers, such as rifampicin, ketoconazole, theophylline, carbamazepine, phenytoin, phenobarbital and St. John's wort, clobazam, macrolides, verapamil, fluoxetine, amiodarone and tacrolimus. - Patients using anticoagulant, like vitamin K anticoagulant medicines, as warfarin.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo oral drops
use of placebo for 12 weeks
Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg
use of cannabidiol + canabigerol + thc for 12 weeks

Locations

Country Name City State
Brazil Centro de Pesquisa Clinica Hospital Israelita Albert Einstein São Paulo

Sponsors (2)

Lead Sponsor Collaborator
Hospital Israelita Albert Einstein Industria Farmacêutica Health Meds

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Migraine days The primary outcome will be the reduction in migraine days observed between the baseline period (4 weeks before randomization) and the final visit 12 weeks of intervention (CBD+CBG+THC or placebo) 16 weeks
Secondary Headache days The primary outcome will be the reduction in headache days observed between the baseline period (4 weeks before randomization) and the final visit 12 weeks of intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary migraine duration the attack duration in hours observed before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary migraine intensity the migraine attack intensity measured in a 3 point scale (1- mild; 2 - moderate; 3 - severe) before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary pain medicine intake the amount of pain medicine intake as needed before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary number of patients with migraine reduction greater than 50% the number of patients with migraine reduction greater than 50% before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary number of patients with headache reduction greater than 50% the number of patients with migraine reduction greater than 50% before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary Change in MIDAS score the observed change in MIDAS score, before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary Change in HIT-6 score the observed reduction in HIT-6 score, before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary Change in Beck's Anxiety Inventory scores the observed change in BAI score, before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary Change in Beck's Depression Inventory scores the observed change in BDI score, before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary Change in Severity of Dependence Scale scores the observed change in SDS score, before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
Secondary Change in Epworth Sleepiness Scale scores the observed change in Epworth score, before and after the intervention (CBD+CBG+THC or placebo) 12 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04520425 - Osteopathic Manipulative Techniques for the Treatment of Chronic Migraine Headaches N/A
Recruiting NCT06247592 - Pulse Radiofrequency and Occipital Nerve Block for Chronic Migraine Patients N/A
Recruiting NCT06133491 - Open Label, 6-month Study for High Frequency and Chronic Migraine,
Recruiting NCT06138171 - Personality, Defences, Central Sensitization, and Trauma in Women With Chronic Migraine, Fibromyalgia, and Vulvodynia
Active, not recruiting NCT06109389 - The Efficacy Of Lidocaine Infusion IN Chronic Unilateral Migraine Headache Phase 2
Completed NCT04871581 - Adjunctive Treatment of Chronic Migraine Using an Oral Dental Device N/A
Withdrawn NCT01749423 - A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines N/A
Terminated NCT04349176 - Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units? Phase 3
Completed NCT05381129 - The Effect of Accompanying Temporomandibular Joint Dysfunction in Patients With Chronic Migraine N/A
Completed NCT05381012 - Fibromyalgia Syndrome on Patients With Chronic Migraine N/A
Withdrawn NCT03465826 - Developing a Mobile Health Pain-Coping Skills Training Program for the Treatment of Chronic Migraine: AIM 4 N/A
Completed NCT03767062 - Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches N/A
Completed NCT05748535 - Effect of Auricular Vagus Nerve Stimulation in Women With Migraine Disease N/A
Recruiting NCT05724771 - COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study Phase 4
Recruiting NCT05313503 - KETOMIGRAINE: Ketogenic Diet in Drug-resistant Chronic Migraineurs N/A
Recruiting NCT05079659 - Rate , Predictors and Outcome of Chronic Migraine
Completed NCT03698409 - Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine. Phase 4
Completed NCT06118190 - Mesotherapy in the Treatment of Chronic Migraine N/A
Completed NCT04017741 - A Study Investigating the Efficacy of GON Blocks. Phase 4
Completed NCT05679908 - A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine Phase 2